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Background: Novel allelic variants in the promoter of the canine cyclooxygenase-2 (Cox-2) gene are associated
with renal dysplasia (RD). These variants consist of either deletions of putative SP1 transcription factor-binding sites
or insertions of tandem repeats of SP1-binding sites located in the CpG island just upstream of the ATG translation
initiation site. The canine Cox-2 gene was studied because Cox-2-deficient mice have renal abnormalities and a
pathology that is strikingly similar to RD in dogs.
Findings: The allelic variants were associated with hypermethylation of the Cox-2 promoter only in clinical cases of
RD. The wild-type allele was never methylated, even in clinical cases that were heterozygous for a mutant allele. In
cases that were biopsy-negative, the promoter remained unmethylated, regardless of the genotype. Methylated
DNA was found in DNA from various adult tissues of dogs with clinical RD.
Conclusions: The mechanism of action of the allelic variation in the canine Cox-2 promoter most likely involves
variation in the extent of epigenetic downregulation of this gene. This epigenetic downregulation must have
occurred early in development because methylated Cox-2 promoter DNA sequences are found in various adult
tissues.
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Renal dysplasia (RD) or improper development of the
kidneys is a life-threatening disease that can result in
end-stage renal failure. In all species, RD can be genetic
or acquired. There has been intense speculation regard-
ing the role of epigenetic modifications in kidney devel-
opment [1]; however, to my knowledge this report is the
first documented case involving allele-specific epigenetic
changes associated with kidney disease.
Cyclooxygenase-2 (Cox-2) is generally considered to
be a rate-limiting enzyme for prostaglandin synthesis in
response to biological events such as injury, inflamma-
tion, and proliferation [2]. Transcriptional regulation of
Cox-2 is complex. In most tissues, Cox-2 requires acti-
vation by inflammatory or other stimuli and is regulated
by numerous 5′ transcription factors in addition to post-
transcriptional regulation through elements at the 3′Correspondence: info@dogenes.com
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unless otherwise stated.untranslated region of the gene [3]. However, in the
adult kidney and several other organs, Cox-2 is constitu-
tively expressed in various cell types, and its expression
increases under non-physiological conditions [4]. Fur-
thermore, Cox-2 also functions as a developmental gene,
as evidenced by knockout and knockdown mouse mo-
dels that show abnormal kidney development [5-7]. Cox-2
knockdown mice have a less severe phenotype than Cox-2
knockout strains. Furthermore, expression studies in de-
veloping rats show that Cox-2 has highly specific and
tightly regulated gene expression.
In the developing rat Cox-2 protein and mRNA are
not detected until mid-gestation, but Cox-2 expression
is high from day 15 and increases up to day 20. In the
fetus, Cox-2 expression is restricted to the skin, heart,
cartilage, and kidney [8]. A similar pattern of Cox-2 ex-
pression has been reported during mouse and human
development [9,10].
Cox-2-deficient mice have renal abnormalities and
a pathology that is very similar to RD in dogs [5,6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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allelic variants with insertions or deletions of SP1-
binding sites just upstream of the ATG translation
start site [11].
There are four allelic variants of the wild-type allele,
and sequence numbering in all alleles is relative to the
translation start codon. Allele 1 contains a 6-nucleotide
deletion (CCGCCG) at position −73 of the canine Cox-2
gene and a deletion of 11 nucleotides at position −37
(CCGCCCGCGCT). Allele 2 contains an insertion of 12
nucleotides (CGCCTCCGCCTC) starting at position −78.
Allele 3 contains an insertion of 24 nucleotides (CGCC
TCCGCCTCCGCCTCCGCCGC) at position −78. The
first 12 nucleotides of this 24-nucleotide insertion com-
prise the insertion in allele 2. Allele 4 comprises the
6-nucleotide deletion at position −73 found in allele 1
(Figure 1). The frequency of the mutant alleles varies
among different breeds, as shown in a previous study [11].
These allelic variants exist within a large CpG island
in the Cox-2 promoter near the translation start site; this
CpG island is approximately 450 nucleotides long (as
predicted by MethPrimer) [12]. Normally, the CpG
island in the human Cox-2 promoter is unmethyla-
ted. However, hypermethylation of the human Cox-2
CpG island has been identified in some types of can-
cer [13,14], in which the level of Cox-2 repression
increased with higher levels of methylation.Figure 1 Allelic variants in the cyclooxygenase-2 (Cox-2) promoter, ju
DNA sequences that are deleted; these sequences are boxed with the num
2 is underlined and not shaded. Allele 3 contains a further insertion of seq
of the inserted sequences in allele 2. Allelic variant 4 contains a deletion of
below the box. The sequences of the complete promoter region and 5′ un
AY927786.1.The aim of this study was to determine whether these
allelic variants cause hypermethylation of the CpG island
in the canine Cox-2 promoter in clinical cases of RD.
Such hypermethylation would provide a mechanism by
which these alleles could decrease or silence COX-2 ex-
pression during a critical time of development and gen-
erate a phenotype that is similar to the mouse knockout
[5,6] and knockdown [7] models of RD.
DNA samples used in the study
DNA samples were obtained from cheek cells or pre-
served kidney tissue (preserved in RNALater (Qiagen Inc.,
Valencia, CA, USA) or as formalin-fixed and paraffin-
embedded tissue sections). All of the samples were har-
vested in a previous study [11]. For bisulfite conversion,
the DNA from the cheek swabs was concentrated using a
DNA Clean & Concentrator™ kit from Zymo Research
Corp. (Irvine, CA, USA). The DNA from kidney tissue
preserved in RNALater was extracted using a mini gDNA
extraction kit (Zymo Research Corp.).
DNA samples were obtained from five dogs with clinical
cases of moderate to severe RD (>35% fetal glomeruli on
biopsy). In addition, there were three biopsy-negative sam-
ples and five samples from randomly chosen dogs with a
homozygous wild-type Cox-2 genotype. A negative biopsy
indicated that no fetal glomeruli were present in the kid-
ney section examined.st upstream of the ATG translation start site. Allelic variant 1 has
ber 1 below the box. Allelic variants 2 and 3 contain insertions. Allele
uences at nucleotide −78 relative to the ATG start, and is a duplication
6 nucleotides (CCGCCG) and is boxed and marked with the number 4
translated region are deposited in GenBank under accession number
Figure 2 Representative results of methylation-specific PCR experiments with the dogs described in Table 1. The sizes of the alleles are
as follows: wild-type allele, 187 bp; Allele 1, 170 bp; Allele 2, 99 bp; Allele 3, 211 bp; Allele 4, 181 bp. Cases 1–5 are biopsy-positive dogs. Cases 6–8 are
biopsy-negative dogs. U is the unmethylated DNA from the methylation-specific PCR, and M is the methylated DNA. The final two lanes represent
negative controls (no DNA) for the methylation-specific PCR experiments. In the case of heterozygotes, a heteroduplex band (marked with an H) is
presented above the actual alleles. wt, Wild-type.
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The DNA was bisulfite modified using the EZ DNA
Methylation-Lightning™ Kit (Zymo Research Corp.). Pri-
mers for methylation-specific PCR [15] and DNA sequen-
cing were chosen using MethPrimer [12] as follows.
Methylated DNA-specific primer set:
M forward primer, 5′-TGTTTTTTTTAGCGTCGTA
GTTTC-3′
M reverse primer, 5′-AAAAACCAAATACCCACCT
ACG-3′




CAC-3′Table 1 Genotypes and clinical information for dogs used in
Case number Breed Biopsy Genotype Methylat
1 Cocker spaniel + Allele1/Allele1 Allele1
2 Shih Tzu + Allele1/wt Allele1
3 Standard poodle + Allele2/wt Allele2
4 Lhasa apso + Allele2/Allele3 Allele2/Al
5 Gordon Setter + Allele4/wt Allele4
6 Lhasa apso − wt/wt None
7 Miniature Schnauzer − Allele1/Allele1 None
8 Lhasa apso − Allele2/Allele2 None
9 English cocker spaniel n/a wt/wt None
10 Boxer n/a wt/wt None
11 Collie n/a wt/wt None
12 Collie n/a wt/wt None
13 Cocker spaniel n/a wt/wt NoneThe PCR conditions were 95°C for 1 min, followed by
35 cycles of 95°C for 15 s, 52°C for 15 s, and 72°C for
10 s, using MyTaq hot-start polymerase (Bioline, Taunton,
MA, USA).
To obtain sufficient DNA for sequencing of the me-
thylated DNA, the methylation-specific PCR products
were separated on a PCR-CheckIT gel (Elchrom Scien-
tific AG, Cham, Switzerland) with 1× buffer as recom-
mended by the manufacturer. Individual alleles were
recovered from the gel using BandPick™ (Elchrom Scien-
tific) and re-amplified with the primers described above
for DNA sequencing. The DNA was re-amplified using
MyTaq hot-start polymerase for 30 cycles. The frag-
ments were sequenced by Macrogen Corp. (Rockville
MD, USA).this study
ed DNA products Source of DNA Age at death
from renal failure
Formalin preserved kidney tissue 2.5 years
Cheek cells 4 months
Kidney 9 months
lele3 Kidney 8 years









Figure 3 Representative electropherograms from the DNA sequencing of bisulfite-converted DNA. (A) DNA that has not been converted
with bisulfite (normal sequence). The primer set for this experiment was primer set 1 from reference [11]. (B) Wild-type allele showing that the
CpG island of the Cox-2 promoter is unmethylated. (C) Electropherogram showing dense methylation of multiple alleles throughout the CpG
island of the cyclooxygenase-2 (Cox-2) gene. (D) Electropherogram from Case number 2 (Shiz tzu) showing complete hypermethylation of the
Cox-2 CpG island.
Whiteley Clinical Epigenetics 2014, 6:7 Page 4 of 6
http://www.clinicalepigeneticsjournal.com/content/6/1/7
Whiteley Clinical Epigenetics 2014, 6:7 Page 5 of 6
http://www.clinicalepigeneticsjournal.com/content/6/1/7The PCR products from methylation-specific PCR were
separated on a Spreadex 300 gel (Elchrom Scientific) with
1× TAE as the running buffer. Xylene cyanol loading buf-
fer was run to the bottom of the gel.
Results
The results of the methylation-specific PCR experiments
are summarized in Figure 2 and Table 1. The CpG island
of the canine Cox-2 wild-type allele was always unme-
thylated. Methylated DNA was only found in RD dogs
that were either homozygous or heterozygous for a mu-
tant allelic variant. In RD heterozygotes, only the mutant
allele was methylated. In the case of RD dogs that were
homozygous for mutant alleles, both alleles were methyl-
ated. In biopsy-negative dogs that were homozygous
wild type, heterozygous, or homozygous for mutant
alleles, the Cox-2 promoter remained unmethylated
(Figure 2 and Table 1).
Allele1–allele 4 are the variants shown in Figure 1. +,
Indicates that biopsy data showed moderate to severe
renal dysplasia (>35% fetal glomeruli); –, indicates that
no fetal glomeruli were found in the biopsy; n/a, not
available; wt, wild-type.
The methylation-specific PCR experiments were vali-
dated by DNA sequencing. DNA sequencing of methyl-
ated DNA from clinical samples generally showed dense
methylation of multiple alleles. However, in case number
2 (Table 1), the Shih tzu (Allele 1/wild type) allele 1 was
hypermethylated at all CG dinucleotide positions through-
out the amplified product (Figure 3).
Discussion
The first evidence that Cox-2 acts a critical gene in de-
velopment was obtained from Cox-2 knockout mouse
strains, which show severe defects in their kidneys [5,6].
Further studies revealed a specific and tightly regulated
pattern of gene expression in developing rats, mice, and
humans [8-10]. The defects noted in the kidney included
immature glomeruli, and the severity of RD in dogs is
classified by the percentage of fetal glomeruli found on
biopsy.
This study shows that novel allelic variants in the CpG
island of the Cox-2 promoter have aberrant methylation
of the Cox-2 promoter only in clinical cases of RD. The
wild-type alleles are never methylated, even in animals
that are heterozygous for a mutant allele. This in effect
provides an internal control for methylation and shows
a distinct resistance of the wild-type chromosome to
methylation. This finding of methylation resistance was
further reinforced by the lack of methylation in homozy-
gous wild-type controls. These results provide strong
evidence that the mechanism of action of the mutant
alleles likely involves some degree of transcriptional down-
regulation via methylation of the CpG island in the Cox-2promoter. Such a mechanism is supported by a previous
study on cancer cell lines, in which methylation of the
Cox-2 promoter resulted in decreased expression or silen-
cing of the Cox-2 gene, depending on the extent of methy-
lation [13,14]. These findings are consistent in different
types of cancer. The results of the present study also ex-
plain the mode of inheritance as dominant with incom-
plete penetrance because the degree of methylation varies
between the clinical cases. The occurrence of aberrant
methylation in different breeds and therefore in different
genetic backgrounds reinforces the notion of a universal
mechanism of action.
In general, Cox-2 is an inducible enzyme, but it has
a basal level of expression in a subset of adult kidney
tissues that is elevated in response to external stimuli,
highlighting the complex regulation of this gene [3].
In a previous study, RT-PCR showed Cox-2 expres-
sion in adult kidneys, although this expression could
have been in response to the inflammation intrinsic
to this disease, and the expression may be regulated
by transcription factors other than tissue-specific or de-
velopmental transcription factors [11]. Although Cox-2
is expressed in a limited number of fetal tissues, the
only defects observed in Cox-2 knockout and knock-
down mouse models are dysplastic kidneys, suggesting
that downregulation of Cox-2 may be tissue-specific in
the developing fetus [5-7]. Embryogenesis would therefore
be the critical time to evaluate downregulation of Cox-2;
however, observation during embryogenesis is not prac-
tical in dogs.
For the proposed mechanism of action to work, me-
thylated DNA must be present in kidney tissues. How-
ever, methylated DNA was also found in cheek cells,
indicating that the epigenetic event occurred early in de-
velopment and in cells of both mesodermal and ectoder-
mal origin. The methylation may thus have been caused
by either environmental factors or other genes.
There has been intense speculation regarding the role
of epigenetics in kidney disease, and this study rep-
resents the first example of DNA methylation of a CpG
island that is likely to be involved in a developmental
disease process. Other genetically inherited dominant
diseases with incomplete penetrance may involve a simi-
lar mechanism.
Abbreviations
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